MY135452A - 2-methyl-thieno-benzodiazepine lyophilized formulation - Google Patents

2-methyl-thieno-benzodiazepine lyophilized formulation

Info

Publication number
MY135452A
MY135452A MYPI20022723A MYPI20022723A MY135452A MY 135452 A MY135452 A MY 135452A MY PI20022723 A MYPI20022723 A MY PI20022723A MY PI20022723 A MYPI20022723 A MY PI20022723A MY 135452 A MY135452 A MY 135452A
Authority
MY
Malaysia
Prior art keywords
benzodiazepine
thieno
methyl
lyophilized formulation
formulation
Prior art date
Application number
MYPI20022723A
Other languages
English (en)
Inventor
Kurt Douglas Dekemper
Alan Lee Fites
Steven Lamar Nail
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY135452A publication Critical patent/MY135452A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MYPI20022723A 2001-07-20 2002-07-18 2-methyl-thieno-benzodiazepine lyophilized formulation MY135452A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30682901P 2001-07-20 2001-07-20
US38647402P 2002-06-07 2002-06-07

Publications (1)

Publication Number Publication Date
MY135452A true MY135452A (en) 2008-04-30

Family

ID=26975390

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20022723A MY135452A (en) 2001-07-20 2002-07-18 2-methyl-thieno-benzodiazepine lyophilized formulation

Country Status (32)

Country Link
US (1) US20040176357A1 (cg-RX-API-DMAC7.html)
EP (1) EP1423124B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004537546A (cg-RX-API-DMAC7.html)
KR (1) KR20040017330A (cg-RX-API-DMAC7.html)
CN (1) CN1537007A (cg-RX-API-DMAC7.html)
AR (1) AR036180A1 (cg-RX-API-DMAC7.html)
AT (1) ATE369137T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002320134B2 (cg-RX-API-DMAC7.html)
BR (1) BR0211250A (cg-RX-API-DMAC7.html)
CA (1) CA2448724A1 (cg-RX-API-DMAC7.html)
CO (1) CO5540279A2 (cg-RX-API-DMAC7.html)
CY (1) CY1107759T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ200484A3 (cg-RX-API-DMAC7.html)
DE (1) DE60221674T2 (cg-RX-API-DMAC7.html)
DK (1) DK1423124T3 (cg-RX-API-DMAC7.html)
EA (1) EA006506B1 (cg-RX-API-DMAC7.html)
ES (1) ES2289126T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20040037A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0401157A3 (cg-RX-API-DMAC7.html)
IL (1) IL159098A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000541A (cg-RX-API-DMAC7.html)
MY (1) MY135452A (cg-RX-API-DMAC7.html)
NZ (1) NZ529667A (cg-RX-API-DMAC7.html)
PE (1) PE20030281A1 (cg-RX-API-DMAC7.html)
PL (1) PL366614A1 (cg-RX-API-DMAC7.html)
PT (1) PT1423124E (cg-RX-API-DMAC7.html)
SI (1) SI1423124T1 (cg-RX-API-DMAC7.html)
SK (1) SK182004A3 (cg-RX-API-DMAC7.html)
SV (1) SV2003001179A (cg-RX-API-DMAC7.html)
UA (1) UA80095C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003007912A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200400798B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323459B2 (en) * 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
EP1709053B1 (en) 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
WO2006076124A2 (en) * 2004-12-16 2006-07-20 Nektar Therapeutics Stable, non-crystalline formulation comprising olanzapine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
CN111836615A (zh) * 2018-01-05 2020-10-27 英倍尔药业股份有限公司 通过精密鼻装置的奥氮平的鼻内递送
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂
WO2025056094A1 (zh) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 一种冻干制剂和注射液及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421297B1 (en) * 1989-09-30 1993-12-01 Eisai Co., Ltd. Injectable preparations containing cephalosporin medicament and the use thereof
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
HRP20040037A2 (en) 2004-06-30
US20040176357A1 (en) 2004-09-09
ZA200400798B (en) 2005-07-27
DK1423124T3 (da) 2007-12-03
ATE369137T1 (de) 2007-08-15
PT1423124E (pt) 2007-10-29
HUP0401157A2 (hu) 2004-10-28
SV2003001179A (es) 2003-07-29
JP2004537546A (ja) 2004-12-16
WO2003007912A3 (en) 2003-05-01
MXPA04000541A (es) 2004-05-04
PL366614A1 (en) 2005-02-07
IL159098A0 (en) 2004-05-12
DE60221674D1 (de) 2007-09-20
NZ529667A (en) 2006-02-24
KR20040017330A (ko) 2004-02-26
AU2002320134B2 (en) 2007-04-05
SK182004A3 (en) 2004-09-08
AR036180A1 (es) 2004-08-18
SI1423124T1 (sl) 2008-02-29
PE20030281A1 (es) 2003-03-27
CZ200484A3 (cs) 2005-01-12
HUP0401157A3 (en) 2008-01-28
BR0211250A (pt) 2004-07-27
EP1423124B1 (en) 2007-08-08
CY1107759T1 (el) 2013-06-19
WO2003007912A2 (en) 2003-01-30
CO5540279A2 (es) 2005-07-29
EA200400211A1 (ru) 2004-06-24
CA2448724A1 (en) 2003-01-30
CN1537007A (zh) 2004-10-13
UA80095C2 (en) 2007-08-27
HK1066484A1 (en) 2005-03-24
EP1423124A2 (en) 2004-06-02
DE60221674T2 (de) 2008-04-30
EA006506B1 (ru) 2005-12-29
ES2289126T3 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
MXPA01002456A (es) Accesorio de conducto electrico con o sin base adaptadora.
EP1439796B8 (en) Areal implant
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
EG23400A (en) Database.
ZA200307646B (en) Benzamidine derivative.
EG23368A (en) Antimicrobially-treated fabrics.
MXPA03005445A (es) Barra colectora 12c para aislar los circuitos integrados seleccionados para una comunicacion rapida de barra colectora 12c.
YU15299A (sh) Farmaceutski sastavi
MXPA03003375A (es) Compresor lineal.
DE60120712D1 (en) Kallikrein gen
EP2348031A3 (en) 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
MXPA03008500A (es) Composiciones elastomericas de alta traccion y resistentes al desgaste.
CY1107759T1 (el) Λυοφιλισμενη συνταγοποιηση που περιλαμβανει ολανζαπινη
AU148078S (en) Bottle
MXPA03008164A (es) Agentes anti-epileptogenos.
ZA200103011B (en) Dispersions.
MXPA02011148A (es) Formulaciones de latex con amarillamiento reducido.
AP2003002914A0 (en) Novel expression vectors and uses thereof.
CA99324S (en) Picture hanger
ZA200309578B (en) Male contraceptives.
AUPR246301A0 (en) F.l.o.e.s, s.p.l.s.d
GB0102579D0 (en) P.I.N. update
ZA200303136B (en) Kahalalide F formulation.
JO2151B1 (en) Toilet (T.S)
ECSP044949A (es) Formulacion liofilizada de 2-metil-tieno-benzodiazepina